Ann: Appendix 3B - Release of Shares from Escrow, page-46

Not much talk around, the dumb money is slowly exiting.

Little do they know the re-rate which will occur when BGT announce a few blockbuster partnerships targeting multibillion dollar verticals all of which haven't seen any breakthroughs in over a decade. Best of all we are well funded to see commercial objectives met.

Current sellers must be listening to the above noise. The objective since listing has always been to test Flavocides unique Mode of Action and efficacy which builds out compelling data and attracts majors.

The amount of positive newsflow especially since the Virbac withdrawal has been outstanding and only reaffirms the potential of this technology. The CEO has been on board less than a year and has accelerated testing across the spectrum of insects, advanced Qcide and kicked off a SAB.

The bottom seems to be in with buyers happy to soak up stock 12-13c at the giveaway price of a $9M EV which is why I've averaged down heavily. I don't believe we will see a share price close to 10c again.